| Literature DB >> 35354368 |
Kanako Otani1, Mayuko Saito1, Michiko Okamoto1, Raita Tamaki2,3, Mariko Saito-Obata1, Taro Kamigaki1, Irene C Lirio4, Edelwisa Segubre-Mercado4, Veronica Tallo4, Socorro Lupisan4, Hitoshi Oshitani5.
Abstract
BACKGROUND: Lower respiratory tract infection (LRTI) is an important cause of morbidity and mortality in infants and young children. However, the etiological role of viruses and the timing of developing LRTI are not well defined.Entities:
Keywords: Birth cohort; Incidence; Lower respiratory tract infection; Philippines; Respiratory virus
Mesh:
Year: 2022 PMID: 35354368 PMCID: PMC8966153 DOI: 10.1186/s12879-022-07289-3
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Schematic representation of the study participants and LRTI episodes detected in the birth cohort in Biliran, Philippines, from March 2014 to June 2016. aRespiratory symptoms included cough, difficulty breathing or coryza. bDiagnosis of severe pneumonia was based on the criteria of the Integrated Management of Childhood Illness (IMCI). Ten LRTI episodes were classified as undefined LRTI because SpO2 data were missing (n = 2) or it was not possible to assess as its measurement was performed after starting oxygen treatment (n = 8). Abbreviation: LRTI, lower respiratory tract infection; SpO2, percutaneous oxygen saturation. Almost all children in the study area were participated the study, though approximately 10 children refused to participate. Within 419 children, 183 children were followed until 1 year of age and 64 children were followed until 2 years of age, whereas 84 children were not followed until 6 months of age
Incidence rates of LRTIs per 100 child-years and IRRs for severe LRTI compared to non-severe LRTI in Biliran, Philippines, from March 2014 to June 2016
| 0–5 months | 6–11 months | First year of life (0–11 months) | Second year of life (12–23 months) | Total | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LRTI classification | n | IR [95% CI] | IRR [95% CI] | n | IR [95% CI] | IRR [95% CI] | n | IR [95% CI] | IRR [95% CI] | n | IR [95% CI] | IRR [95% CI] | n | IR [95% CI] | IRR [95% CI] |
| Non-severe | 77 | 44.0 [34.7–54.9] | 1 | 63 | 43.2 [33.2–55.3] | 1 | 140 | 43.6 [36.7–51.5] | 1 | 93 | 61.1 [49.3–74.9] | 1 | 233 | 49.3 [43.1–56.0] | 1 |
| Severe | 45 | 25.7 [18.7–34.4] | 0.58 [0.40–0.86] | 36 | 24.7 [17.3–34.2] | 0.57 [0.37–0.87] | 81 | 25.2 [20.0–31.4] | 0.58 [0.43–0.77] | 26 | 17.1 [11.2–25.0] | 0.28 [0.17–0.44] | 107 | 22.6 [18.5–27.3] | 0.46 [0.36–0.58] |
| Undefined | 2 | – | – | 4 | – | – | 6 | – | – | 4 | – | – | 10 | – | – |
| Total | 124 | 70.8 [58.9–84.4] | – | 103 | 70.7 [57.7–85.7] | – | 227 | 70.7 [61.8–80.6] | – | 123 | 80.8 [67.2–96.5] | – | 350 | 74.0 [66.4–82.2] | – |
Total LTRTI included non-severe LRTI, sever LRTI and undefined LRTI. Observed child-years were 175.2, 145.7, and 152.2 at age 0–5, 6–11, and 12–23 months, respectively
LRTI, lower respiratory tract infection; IR, incidence rate; IRR, incidence rate ratio; 95% CI, 95% confidence interval
Fig. 2Cumulative proportion of children who developed first and subsequent LRTI. A Survival curves show cumulative proportions (%) of children who developed the first through fifth total LRTI episodes, including “non-severe LRTI”, “severe LRTI” and “undefined LRTI”. Although four children developed LRTI six times, the sixth episode is not shown in the figure. B Curves show the cumulative proportion (%) of children who developed "severe LRTI". Although two children developed severe LRTI four times and one developed it five times, the fourth and fifth episodes are not shown in the figure). Percentages (shown in brackets) show the cumulative proportion at 24 months of age. Abbreviation: LRTI, lower respiratory tract infection
Detected viruses and subtypes or species from cases with LRTI in Biliran, Philippines, from March 2014 to June 2016
| Detected virus | Non-severe LRTI | Severe LRTI | Undefined LRTI | Total |
|---|---|---|---|---|
| AdV | 3 (1.4%) | 0 (0.0%) | 0 (0.0%) | 3 (0.9%) |
| RV | 59 (27.3%) | 26 (25.0%) | 2 (22.2%) | 87 (26.4%) |
| RV-A | 33 | 13 | 2 | 48 |
| RV-B | 5 | 0 | 0 | 5 |
| RV-C | 21 | 13 | 0 | 34 |
| EV | 6 (2.8%) | 4 (3.9%) | 0 (0.0%) | 10 (3.0%) |
| EV-A | 1 | 0 | 0 | 1 |
| EV-B | 3 | 1 | 0 | 4 |
| EV-C | 1 | 0 | 0 | 1 |
| EV-D (D68) | 1 | 3 | 0 | 4 |
| RSV | 30 (13.9%) | 23 (22.1%) | 3 (33.3%) | 56 (17.0%) |
| RSV-A | 3 | 9 | 1 | 13 |
| RSV-B | 27 | 12 | 2 | 41 |
| RSV-untyped | 0 | 2 | 0 | 2 |
| MPV | 6 (2.8%) | 3 (2.9%) | 0 (0.0%) | 9 (2.7%) |
| PIV | 22 (10.2%) | 6 (5.8%) | 0 (0.0%) | 28 (8.5%) |
| PIV-1 | 3 | 3 | 0 | 6 |
| PIV-2 | 1 | 0 | 0 | 1 |
| PIV-3 | 17 | 3 | 0 | 20 |
| PIV-4 | 1 | 0 | 0 | 1 |
| IFV | 11 (5.1%) | 7 (6.7%) | 1 (11.1%) | 19 (5.8%) |
| IFV-A | 10 | 6 | 1 | 17 |
| IFV-B | 1 | 1 | 0 | 2 |
| Co-detection | 11 (5.1%) | 4 (3.9%) | 1 (11.1%) | 16 (4.9%) |
| Negative | 68 (31.5%) | 31 (29.8%) | 2 (22.2%) | 101 (30.7%) |
| Sub-total | 216 (100.0%) | 104 (100.0%) | 9 (100.0%) | 329 (100.0%) |
| Not tested | 17 | 3 | 9 | 21 |
| Total | 233 | 107 | 10 | 350 |
LRTI, lower respiratory tract infection; AdV, Adenovirus; RV, Rhinovirus; EV, Enterovirus; RSV, Respiratory syncytial virus; MPV, Human metapneumovirus; PIV, Parainfluenza virus; IFV, Influenza virus
Fig. 3Cumulative proportion of children who developed non-severe and severe virus-specific LRTI by virus. The number of episodes (non-severe LRTI, severe LRTI) used for the analysis were AdV (3, 0), RV (59, 26), EV (6, 4), RSV (30, 23), MPV (6, 3), PIV (22, 6) and IFV (11, 7), respectively. Abbreviation: LRTI, lower respiratory tract infection; AdV, adenovirus; RV, rhinovirus; EV, enterovirus; RSV, respiratory syncytial virus; MPV, human metapneumovirus; PIV, para influenzavirus; IFV, influenza virus
Incidence rates of virus-specific LRTIs per 100 child-years and IRRs for severe LRTI compared to non-severe LRTI in Biliran, Philippines, from March 2014 to June 2016
| Detected virus | LRTI classification | 0–5 months | 6–11 months | 12–23 months | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | IR | [95%CI] | IRR | [95%CI] | n | IR | [95%CI] | IRR | [95%CI] | n | IR | [95%CI] | IRR | [95%CI] | ||
| AdV | Non-severe | 0 | 0.0 | [0.0–2.1] | 1 | 2 | 1.4 | [0.2–5.0] | 1 | 1 | 0.7 | [0.0–3.7] | 1 | |||
| Severe | 0 | 0.0 | [0.0–2.1] | 0.00 | [0.00–0.00] | 0 | 0.0 | [0.0–2.5] | 0.00 | [0.00–5.32] | 0 | 0.0 | [0.0–2.4] | 0.00 | [0.00–39.00] | |
| Total | 0 | 0.0 | [0.0–2.1] | – | – | 2 | 1.4 | [0.2–5.0] | – | – | 1 | 0.7 | [0.0–3.7] | – | – | |
| RV | Non-severe | 24 | 13.7 | [8.8–20.4] | 1 | 13 | 8.9 | [4.8–15.3] | 1 | 22 | 14.5 | [9.1–21.9] | 1 | |||
| Severe | 15 | 8.6 | [4.8–14.1] | 0.63 | [0.30–1.24] | 7 | 4.8 | [1.9–9.9] | 0.54 | [0.18–1.45] | 4 | 2.6 | [0.7–6.7] | 0.18 | [0.05–0.54] | |
| Total | 39 | 22.3 | [15.8–30.4] | – | – | 21 | 14.4 | [8.9–22.0] | - | - | 27 | 17.7 | [11.7–25.8] | – | – | |
| EV | Non-severe | 1 | 0.6 | [0.0–3.2] | 1 | 2 | 1.4 | [0.2–5.0] | 1 | 3 | 2.0 | [0.4–5.8] | 1 | |||
| Severe | 2 | 1.1 | [0.1–4.1] | 2.00 | [0.10–117.99] | 1 | 0.7 | [0.0–0.0] | 0.50 | [0.01–9.60] | 1 | 0.7 | [0.0–3.7] | 0.33 | [0.01–4.15] | |
| Total | 3 | 1.7 | [0.4–5.0] | – | – | 3 | 2.1 | [0.4–6.0] | - | - | 4 | 2.6 | [0.7–6.7] | – | – | |
| RSV | Non-severe | 15 | 8.6 | [4.8–14.1] | 1 | 3 | 2.1 | [0.4–6.0] | 1 | 12 | 7.9 | [4.1–13.8] | 1 | |||
| Severe | 11 | 6.3 | [3.1–11.2] | 0.73 | [0.30–1.71] | 7 | 4.8 | [1.9–9.9] | 2.33 | [0.53–13.98] | 5 | 3.3 | [1.1–7.7] | 0.42 | [0.11–1.27] | |
| Total | 27 | 15.4 | [10.2–22.4] | – | – | 11 | 7.6 | [3.8–13.5] | – | – | 18 | 11.8 | [7.0–18.7] | – | – | |
| MPV | Non-severe | 1 | 0.6 | [0.0–3.2] | 1 | 1 | 0.7 | [0.0–3.8] | 1 | 4 | 2.6 | [0.7–6.7] | 1 | |||
| Severe | 1 | 0.6 | [0.0–3.2] | 1.00 | [0.01–78.50] | 0 | 0.0 | [0.0–2.5] | 0.00 | [0.00–39.00] | 2 | 1.3 | [0.2–4.7] | 0.50 | [0.05–3.49] | |
| Total | 2 | 1.1 | [0.1–4.1] | – | – | 1 | 0.7 | [0.0–3.8] | – | – | 6 | 3.9 | [1.5–8.6] | – | – | |
| PIV | Non-severe | 4 | 2.3 | [0.6–5.8] | 1 | 7 | 4.8 | [1.9–9.9] | 1 | 11 | 7.2 | [3.6–12.9] | 1 | |||
| Severe | 2 | 1.1 | [0.1–4.1] | 0.50 | [0.05–3.49] | 4 | 2.7 | [0.7–7.0] | 0.57 | [0.12–2.25] | 0 | 0.0 | [0.0–2.4] | 0.00 | [0.00–0.40] | |
| Total | 6 | 3.4 | [1.37.5] | – | – | 11 | 7.6 | [3.8–13.5] | – | – | 11 | 7.2 | [3.6–12.9] | – | – | |
| IFV | Non-severe | 3 | 1.7 | [0.4–5.0] | 1 | 4 | 2.7 | [0.7–7.0] | 1 | 4 | 2.6 | [0.7–6.7] | 1 | |||
| Severe | 1 | 0.6 | [0.0–3.2] | 0.33 | [0.01–4.15] | 3 | 2.1 | [0.4–6.0] | 0.75 | [0.11–4.43] | 3 | 2.0 | [0.4–5.8] | 0.75 | [0.11–4.43] | |
| Total | 5 | 2.9 | [0.9–6.7] | – | – | 7 | 4.8 | [1.9–9.9] | – | – | 7 | 4.6 | [1.9–9.5] | – | – | |
| Co-detection | Non-severe | 7 | 4.0 | [1.6–8.2] | 1 | 3 | 2.1 | [0.4–6.0] | 1 | 1 | 0.7 | [0.0–3.7] | 1 | |||
| Severe | 2 | 1.1 | [0.1–4.1] | 0.29 | [0.03–1.50] | 1 | 0.7 | [0.0–3.8] | 0.33 | [0.01–4.15] | 1 | 0.7 | [0.0–3.7] | 1.00 | [0.01–78.50] | |
| Total | 9 | 5.1 | [2.4–9.8] | – | – | 4 | 2.7 | [0.8–7.0] | – | – | 3 | 2.0 | [0.4–5.8] | – | – | |
| Negative | Non-severe | 20 | 11.4 | [7.0–17.6] | 1 | 20 | 13.7 | [8.4–21.2] | 1 | 28 | 18.4 | [12.2–26.6] | 1 | |||
| Severe | 11 | 6.3 | [3.1–11.2] | 0.55 | [0.24–1.20] | 13 | 8.9 | [4.8–15.3] | 0.65 | [0.30–1.37] | 7 | 4.6 | [1.8–9.5] | 0.25 | [0.09–0.59] | |
| Total | 31 | 17.7 | [12.0–25.1] | – | – | 34 | 23.3 | [16.2–32.6] | – | – | 36 | 23.7 | [16.6–32.8] | – | – | |
| Total | Non-severe | 75 | 42.8 | [33.7–53.7] | 1 | 55 | 37.8 | [28.4–49.1] | 1 | 86 | 56.5 | [45.2–69.8] | 1 | |||
| Severe | 45 | 25.7 | [18.7–34.4] | 0.61 | [0.41–0.88] | 36 | 24.7 | [17.3–34.2] | 0.65 | [0.42–1.01] | 23 | 15.1 | [9.6–22.7] | 0.27 | [0.16–0.43] | |
| Total | 122 | 69.6 | [57.8–83.2] | – | – | 94 | 64.5 | [52.1–79.0] | – | – | 113 | 74.3 | [61.2–89.3] | – | – | |
Total LTRTI included non-severe LRTI, severe LRTI and undefined LRTI. Observed child-years were 175.2, 145.7, and 152.2 at age 0–5, 6–11, and 12–23 months, respectively. Episodes in which samples were not tested for virus detection were excluded (n = 21)
IR, incidence rate; IRR, incidence rate ratio; LRTI, lower respiratory tract infection; 95%CI, 95% confidence interval; AdV, Adenovirus; RV, Rhinovirus; EV, Enterovirus; RSV, Respiratory syncytial virus; MPV, Human metapneumovirus; PIV, Parainfluenza virus; IFV, Influenza virus